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http://www.biomedcentral.com/1471-2458/13/1176STUDY PROTOCOL Open AccessAttentional bias retraining in cigarette smokers
attempting smoking cessation (ARTS): Study
protocol for a double blind randomised
controlled trial
Rachna Begh1,2*, Marcus R Munafò3,4, Saul Shiffman5, Stuart G Ferguson6, Linda Nichols2,
Mohammed A Mohammed7, Roger L Holder2, Stephen Sutton8 and Paul Aveyard1Abstract
Background: Smokers attend preferentially to cigarettes and other smoking-related cues in the environment, in what is
known as an attentional bias. There is evidence that attentional bias may contribute to craving and failure to stop smoking.
Attentional retraining procedures have been used in laboratory studies to train smokers to reduce attentional bias, although
these procedures have not been applied in smoking cessation programmes. This trial will examine the efficacy of multiple
sessions of attentional retraining on attentional bias, craving, and abstinence in smokers attempting cessation.
Methods/Design: This is a double-blind randomised controlled trial. Adult smokers attending a 7-session weekly stop
smoking clinic will be randomised to either a modified visual probe task with attentional retraining or placebo training.
Training will start 1 week prior to quit day and be given weekly for 5 sessions. Both groups will receive 21 mg transdermal
nicotine patches for 8–12 weeks and withdrawal-orientated behavioural support for 7 sessions. Primary outcome measures
are the change in attentional bias reaction time and urge to smoke on the Mood and Physical Symptoms Scale at 4 weeks
post-quit. Secondary outcome measures include differences in withdrawal, time to first lapse and prolonged abstinence at
4 weeks post-quit, which will be biochemically validated at each clinic visit. Follow-up will take place at 8 weeks, 3 months
and 6 months post-quit.
Discussion: This is the first randomised controlled trial of attentional retraining in smokers attempting cessation.
This trial could provide proof of principle for a treatment aimed at a fundamental cause of addiction.
Trial registration: Current Controlled Trials: ISRCTN54375405.Background
Although many people who smoke achieve short-term
success with current smoking cessation interventions,
the rate of relapse to smoking remains high. Over
75% of initially successful quitters return to smoking
within a year, with relapse occurring most commonly
in the first 6 months after cessation [1]. At present,
there is insufficient evidence to support the use of* Correspondence: rachna.begh@phc.ox.ac.uk
1Department of Primary Care Health Sciences, Radcliffe Observatory Quarter,
UK Centre for Tobacco and Alcohol Studies, University of Oxford, Woodstock
Road, Oxford OX2 6GG, UK
2Primary Care Clinical Sciences, University of Birmingham, Birmingham B15
2TT, UK
Full list of author information is available at the end of the article
© 2013 Begh et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.behavioural methods to prevent relapse in individuals
achieving initial abstinence [2]. Most interventions have
typically focused on Marlatt and Gordon’s [3] ‘skills’ based
approach, which attempts to teach patients to identify situ-
ations conducive to relapse and teach cognitive and behav-
ioural coping skills to deal with these situations. However,
there is no evidence that the skills based approach dimin-
ishes or delays relapse to smoking [4] and so new interven-
tions are required.
More recently, there has been increasing interest in
the influence of implicit cognitive processing biases on
our understanding of the relapse process [5]. Attentional
bias, where drug users show excessive attention towards
drug-related cues in the environment, is well-documentedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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[6,7]. Several theoretical models of attentional bias propose
that through repeated drug use, drug-related cues ap-
pear appealing to drug users, ‘grab’ attention and become
‘wanted’ to the extent that behaviour is guided towards
drug use relatively automatically [8,9]. Further theoretical
models propose that increases in attentional bias are both
a cause and consequence of high levels of craving [10].
Thus, smokers with high levels of craving may be more
likely to search the environment for smoking-related cues,
while prolonged attentional processing of smoking-related
cues could increase urges to smoke. There is evidence that
attentional bias is related to drug craving [11], although
this relationship has been reported as somewhat weak
[12]. Attentional bias has also been linked to an increase
in the likelihood of relapse in smokers [13], alcohol users
[14] and heroin addicts [15]. There is also strong anec-
dotal evidence that environmental and situational cues
act as triggers for relapse in abstinent smokers. Control
of attentional processes may therefore play a key role in
preventing relapse among smokers who are attempting
to quit, although current smoking cessation programmes
delivered by the National Health Service (NHS) Stop
Smoking Services (SSS) in the United Kingdom (UK) do
not target attentional biases directly.
Several paradigms measure cognitive processing biases.
The most common among these are the visual probe task
[16] and Stroop task [17]. In the standard version of the
visual probe task, pairs of pictures or words – one drug-
related and one neutral stimulus - are presented briefly
on a computer screen before a probe appears in the loca-
tion formerly occupied by one of the pictures or words.
Smokers, in comparison to non-smokers, have shown
an attentional bias towards smoking by responding faster
to probes that appear in the location of smoking-related
stimuli rather than neutral stimuli [18,19]. Other drug
users have shown an attentional bias towards drug-related
stimuli of their choice; for example, cannabis users are
faster to respond to cannabis-related stimuli than neu-
tral stimuli [20]. Similarly, the addiction Stroop task has
been used extensively to measure selective processing
of drug-related stimuli [21]. Processing biases on the
Stroop task have been demonstrated in smokers who
are typically slower to colour-name smoking-related
stimuli than neutral stimuli [22,23].
There is some evidence to suggest that cognitive pro-
cessing biases are apparent in smokers ever after attempts
to stop smoking. The first study to explore this found that
ex-smokers, who were enrolled in a smoking cessation
programme and had been abstinent from smoking for at
least 1 week, had an intermediate bias for smoking-related
stimuli, in-between that of smokers and non-smokers
[19]. In another study, smokers who were attempting to
quit and smokers without such plans had similar levelsof attentional bias [24]. In contrast to these studies, two
studies found that ex-smokers showed a similar level of
processing bias as never-smokers, while smokers exhib-
ited more bias than both other groups [23,25]. In both
of these studies, ex-smokers had been abstinent for at
least 6 months rather than recently abstinent from
smoking. Thus, data are conflicting but it is possible
that attentional bias persists early in a quit attempt and
resolves with increased duration of abstinence although
no study has examined this. However, if attentional bias
persists for many months, we might speculate that if
there are enduring effects of smoking cues after cessa-
tion as suggested in previous research, abstinence could
be undermined in initially successful quitters.
Cognitive bias modification (CBM) procedures have
been developed in an attempt to change cognitive pro-
cessing biases using modified versions of the visual probe
task and Stroop task [26-33]. CBM procedures are de-
signed to augment or attenuate cognitive processing biases,
providing not only a method of studying the causal rela-
tionship between attentional bias, craving and relapse, but
also a potential treatment for attentional bias in clinical
populations. Attentional retraining (AR) is most com-
monly used in the study of addiction-related attentional
bias. Individuals with specific drug use patterns can be
trained to increase or decrease attentional bias towards
their drug of choice in train-to-attend and train-to-
avoid manipulations, respectively [26,28-30,32]. In the
train-to-attend manipulation, probes replace drug-related
stimuli more frequently than neutral stimuli; by com-
parison in the train-to-avoid manipulation, probes replace
neutral stimuli on a greater number of occasions. Con-
sequently attention is trained towards one particular
stimulus type.
Most investigations of AR in addiction have been con-
ducted in laboratory studies of non-treatment seeking
alcohol users [28,29,32] and more recently, tobacco smokers
[26,30,31]. These studies have typically measured the ef-
fects of AR on subjective outcomes, e.g. craving and be-
havioural outcomes such as drug consumption as well as
the change in attentional bias. In the first of these studies
comparing a train-to-attend with a train-to-avoid manipu-
lation, training towards alcohol-related stimuli was associ-
ated with increases in attentional bias, urge to drink and
actual beer consumption. Conversely, training away from
alcohol-related stimuli was associated with reductions in
attentional bias and beer consumption but not urge to
drink. The study was replicated with the inclusion of a
control group that received no training towards any par-
ticular stimulus type; the predicted direction of change in
attentional bias was observed in the groups trained to at-
tend or avoid alcohol-related stimuli, as well as no change
in attentional bias in the control group [29]. Alcohol crav-
ing increased among participants in the attend group, but
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gencies, i.e. participants who reported the relationship be-
tween the location of the probe and stimulus-presentation
correctly in a post-task questionnaire. However, in con-
trast to the findings of the earlier study, there were no dif-
ferences between groups in the volume of beer consumed.
Schoenmakers and colleagues carried out a similar study
where heavy social drinkers had learned to avoid alcohol-
related stimuli and developed an attentional bias towards
soft drinks, although training had no effect on craving or
drink choice [32].
Only three laboratory studies have published findings
on AR procedures in current tobacco smokers [26,30,31].
The first of these studies found that AR increased atten-
tional bias in participants who were trained towards
smoking-related stimuli and decreased attentional bias
in those trained towards neutral stimuli [26]. Further-
more, when participants were measured on their response
to a lit cigarette following the training procedure, greater
increases in subjective craving were found in male par-
ticipants who attended to smoking-related stimuli than
those trained towards neutral stimuli. However, no effect
of training on smoking topography (e.g. number of puffs
taken, puff duration, etc.) was observed. In a replication
of the study with a no-training control group, atten-
tional bias was greater after training in the attend group
than the avoid and no-training control groups, but these
effects disappeared after 1 day [30]. Neither the train-
to-attend or train-to-avoid manipulations had any effect
on urge to smoke, although unlike in the previous study,
no cue exposure task was used. No group effects of
retraining on motivation to smoke were observed. McHugh
and colleagues compared an avoid group with a no-training
control group and found no change in attentional bias
and no effects of retraining on subjective craving [31].
Unlike the two previous studies, no behavioural measures
of tobacco-seeking were taken.
Collectively, laboratory studies of AR suggest that atten-
tional bias can be modified and that, in some cases, corre-
sponding changes in craving occur. While AR has not
shown any effects on drug-taking behaviour in smokers,
it is worth noting that laboratory studies of AR typically
recruit samples of continuing smokers who are tempor-
arily abstinent for the purpose of the experimental investi-
gation. These smokers presumably have no motivation or
intention to reduce their substance use in comparison to
treatment-seeking smokers. Studies of AR in clinical pop-
ulations are capable of addressing how attentional bias
relates to real-world behaviour – particularly relapse -
in addition to assessing the efficacy of AR as a clinical
intervention.
Only two studies to date have examined the effects
of AR in substance users seeking to reduce or abstain
from drug use [27,33]. In an uncontrolled trial of AR,hazardous and harmful drinkers interested in reducing
their alcohol intake completed 2 or 4 weekly sessions of
AR on a modified Stroop task, respectively [27]. After
treatment was complete, processing biases towards alcohol-
related stimuli reduced in both groups, as did alcohol
consumption by approximately 10 Units/week (1 Unit is
equivalent to 8 g of ethanol) for the harmful drinkers.
These reductions were also maintained at the 3 month
follow up. Uncontrolled trials in people seeking to change
their behaviour are difficult to interpret, however. In the
only randomised controlled trial of AR in substance
users, Schoenmakers and colleagues found that alcohol-
dependent patients were more able to disengage atten-
tion from alcohol-related stimuli than control patients
after 5 sessions of AR on a modified visual probe task,
given in addition to standard treatment [33]. Moreover,
relapse was delayed by over a month in patients that re-
ceived AR. While there appear to be promising effects
of AR as a clinical intervention in alcohol abusers, little
is known about the clinical value of AR procedures in
smokers attempting to quit.
Rationale for the trial
Resumption of smoking by initially successful quitters is
arguably the greatest public health challenge in smoking
cessation. While there are few interventions at present that
are known to reduce the risk of relapse to smoking [2], the
development of new approaches like AR could be worth-
while. Despite evidence from laboratory studies indicating
that attentional bias can be modified in tobacco smokers
using AR procedures [26,30] and the success of such tasks
on improving clinical outcomes in other addictions [33]
and psychopathologies [34], no study has yet explored
the clinical application of these procedures in treatment-
seeking smokers.
We therefore propose a double-blind randomised con-
trolled trial of multiple sessions of attentional bias retrain-
ing in smokers attempting smoking cessation (ARTS).
This translational study offers the ability to both examine
the benefits of AR on users of stop smoking services
and provide findings to aid our understanding on the
phenomenon of attentional bias and its relation to craving,
withdrawal symptoms, lapses and relapse in smokers
attempting to quit.
Aims and study questions
The aim of the study is to investigate the efficacy of an AR
intervention on attentional bias and smoking cessation
outcomes in smokers undertaking behavioural treatment.
The following study questions will be addressed:
1) Can AR diminish attentional bias in smokers during
cessation; are the effects evident across different
cognitive bias tasks and different types of stimuli?
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sessions - can lead to reductions in attentional bias
in smokers who are attempting cessation. If
retraining is successful, participants should be able
to demonstrate that they can divert their attention
away from smoking cues on a visual probe task.
We expect AR to reduce the degree to which
smokers notice smoking cues in their environment
because they are trained away from attending to them.
Similarly, if AR shows material reductions on one
cognitive bias task, it is plausible that a reduction
may be seen on another task measure - such as the
pictorial Stroop task - if similar attentional processes
are involved. Finally, if AR produces a global change
in attentional bias and not just a task-specific change
in bias towards smoking cues, then smokers should
be able to transfer their ability to divert their
attention away from other smoking cues that
are not featured in the retraining procedure.
2) Does AR affect urges to smoke, cue-induced craving
or withdrawal symptoms in smokers during
cessation?
We will investigate the effects of AR on urges to
smoke, cue-induced craving and withdrawal symptoms
in smokers during their cessation attempt. If AR
procedures are capable of reducing exposure by
diverting attention away from smoking cues, this
in turn could reduce the capacity of these cues to
invoke craving and symptoms of withdrawal.
3) Do the effects of AR on attentional bias persist up to
6 months after cessation?
One marker for the success of AR procedures is to
evaluate whether they produce enduring effects; this
is particularly pertinent if the presence of attentional
bias undermines abstinence [35]. As the durability of
AR remains unclear at present, we will investigate
whether the effects of AR are evident in smokers
after their cessation attempt at follow-up assessments.
4) Does AR reduce the likelihood of relapse in smokers
attempting cessation?
We will assess whether retraining can reduce the
likelihood of relapse in smokers attempting to quit.
If the ability to divert attention away from smoking-
related cues during retraining translated to a
smoker’s natural environment, s/he might experience
less exposure to the environmental cues that would
normally trigger smoking; in time, this could
weaken the stimulus–response association between
smoking cues and smoking behaviour, thus
reducing the likelihood of a lapse occurring.
Alternatively, if attentional avoidance leads to
less instances of craving, this may also in turn
reduce the likelihood of relapse, given that craving
predicts relapse [13,36,37].Methods/design
This is a double blind randomised controlled trial. Par-
ticipants attending a 7-session weekly NHS stop smok-
ing clinic will be individually randomised to either an
intervention group consisting of a modified visual probe
task with AR or a control group with placebo training
(PT). Five sessions of AR or PT will be delivered. Both
groups will receive nicotine replacement therapy (NRT)
in the form of transdermal nicotine patches and stand-
ard withdrawal orientated behavioural support [38].
Inclusion criteria
Participants will be required to meet the following inclu-
sion criteria to be eligible for enrolment into the trial:
1. Aged 18 years or over.
2. Currently smoke at least 10 cigarettes per day or
12.5 grams of tobacco or have a value of at least 10
parts per million (ppm) for exhaled carbon
monoxide (CO).
3. Have normal or corrected-to-normal vision.
4. Informed consent.
5. Are able and willing to complete all study procedures.
Exclusion criteria
Participants will be excluded if they present with any
of the following:
1. A medical condition that prevents them from seeing
the computerised images properly, attending to the
task, or pressing the keyboard buttons on the computer
accurately, or completing any other study procedures.
2. Are currently using nicotine replacement therapy
(NRT), bupropion, nortriptyline, mecamylamine,
reserpine, or varenicline, or undergoing any
treatment for tobacco dependence (e.g. acupuncture)
that they are not willing to cease using and instead
use study medication.
3. Have previously had severe skin reactions to
nicotine patches or severe eczema or other skin
diseases that make patch use hazardous or
undesirable.
4. Have a severe acute or chronic medical or
psychiatric condition or previously diagnosed
clinically important renal or hepatic disease, which
could increase the risk associated with study
participation or could interfere with the
interpretation of study results and, in the judgment
of the investigator, would make the participant
inappropriate for entry into this study.
Withdrawal criteria
It is standard practice in smoking cessation trials to treat
those who fail to attend appointments as having relapsed
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withdrawal from the trial; we consider that the only
withdrawals will be those in which the participant has
asked to be withdrawn. We expect this in less than 5%
of participants. This is standard procedure in smoking
cessation studies.
Participant recruitment
Figure 1 shows the flow of participants through the trial.
Participants will be recruited from West Midlands NHS
SSS. A letter of invitation and a patient information
sheet about the study will be sent from GP practices to
patients that are registered on their databases as smokers.
The letters will ask those patients who wish to take part in
the trial to respond to the study team. In our experience,
we anticipate that 5–10% will respond. Staff within the
NHS SSS will also write to smokers with a history of failed
quit attempts who are on their databases. Preliminary
eligibility to participate will be assessed during telephone
screening and potential participants will be booked in for
an assessment session at the clinic site, similar to that
arranged by the NHS SSS. Written informed consent
will be obtained from all participants at the first session,
which takes place 2 weeks prior to quit day.
Staff training
Research nurses and stop smoking advisors (SSAs) will
be trained to deliver the intervention. All staff will complete
a 2-day NHS stop smoking advisor course. They will alsoAssessed for eligibil
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Figure 1 Flow diagram of participants through trial.attend a training day in which they will be briefed on the
clinical procedure on how to deliver each task and on
use of the trial database. Prior to running a clinic, each
member of staff will observe a baseline session and
week −1 (randomisation) session delivered by the chief
investigator. In turn, the chief investigator will observe
the first two sessions delivered by each nurse/SSA involved
in the study. Regular site visits will be conducted to check
that the intervention is being delivered as per protocol.
Trial procedures
Participants in both trial arms will be seen weekly in
clinics from 2 weeks prior to quit day up to 4 weeks post
quit day. There are ten clinic sessions in total. Random-
isation takes place at the second clinic session, which
initiates the first of the 5 weekly AR/PT sessions. Follow
up visits take place at 8 weeks and 3 months post quit
day, with a final visit arranged at 6 months. Participants
will be paid £15 to complete assessments at 3 month and
6 month follow-up sessions, as these are not therapeutic
encounters. Participants will be reminded to attend their
appointments by telephone or text message. Staff will
complete a case report form (CRF) at each clinic visit,
which contains a checklist of the trial procedures.
Randomisation
Participants will be randomised 1:1 to either AR or PT
using a computer generated simple randomisation scheme,
ordered in random permuted blocks of four. The sequenceity at telephone screening
 assessment
omisation
Allocated to 5 sessions PT (control) 
sment at 4 weeks post-quit
onth follow-up assessment
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a dedicated online trial database by an independent pro-
grammer in the Primary Care Clinical Research and Tri-
als Unit (PCCRTU) at the University of Birmingham. At
1 week prior to quit day, at the start of the clinic ses-
sion, the therapist will access the randomisation section
of the trial database and click on a button that reveals a
letter (‘A’ or ‘B’) to reveal the training task to which the
participant is allocated. The training tasks are contained
within two folders labelled ‘Training A’ or ‘Training B’
on the study laptop, which conceals whether the pro-
cedure is AR or PT. These folders were labelled by an
independent researcher prior to the start of the trial.
Thus the participants, therapists and study staff will be
blinded to allocation, to minimize the risk of bias.
Measures
Table 1 displays the treatment and measurement plan
for the study. The measures consist of the following:
 A baseline questionnaire to collect information on
the demographic and clinical characteristics of
participants. Participant age, gender, ethnicity,
education and employment status are classified
using UK Census 2011 categories [40]. The
questionnaire also contains information on
smoking history including the Fagerström Test of
Nicotine Dependence (FTND) [41], a 6-item
measure assessing the severity of nicotine
dependence.
 A visual probe task and pictorial Stroop task to
assess attentional bias.
 The Mood and Physical Symptoms Scale (MPSS)
[42]. This will be administered at the beginning of
every session to assess urge to smoke and
withdrawal. A modified version of the MPSS will be
used in which each of the nine items is rated on a
scale from 1–7. Items relating to the strength and
frequency of urges can be combined to produce a
composite score (MPSS-C); this is also the case for
combined mood items (MPSS-M). The MPSS was
preferred over other measures such as the
Questionnaire of Smoking Urges because of its
superiority in predicting treatment outcomes
[43,44].
 Exhaled carbon monoxide (CO). Readings will be
taken at the beginning of each session to
biochemically verify smoking status.
 A visual analogue scale (VAS) to measure cue-
induced craving at the beginning of the second session
and following attentional bias assessments.
Measurements will be recorded on a 100 mm scale
from “Not At All” to “Extremely” prior to and after
the task. Ecological Momentary Assessment (EMA) [45] to
collect information on lapses. EMA is an approach
to collecting data in real-time on hand-held elec-
tronic devices; it does not carry the risk of recall bias
like paper diaries [46]. Participants will be given an
electronic diary at the first session and they will be
instructed to record any lapses that occur and the
circumstances in which the lapse occurs up to
5 weeks post quit day. Those who use an electronic
diary will be paid up to £75 at the 8-week session
for completing assessments in this way.
 A questionnaire on knowledge of group allocation.
 A patient satisfaction questionnaire developed by
the study team on the acceptability of the training
tasks. Two items relate to how difficult the task is to
understand and carry out, while a further two items
assess the convenience of task. Items are rated on
a 5-point scale ranging from “not at all difficult”
to “extremely difficult” and “very convenient” to
“very inconvenient”.
Materials
Eighteen picture pairs of smoking-related and matched
neutral pictures will be used across attentional bias as-
sessment and training tasks (picture pairs 1–18). These
stimuli have been tested and applied in previous research
[47,48]. Each set of pictures consists of a colour photo-
graph of a smoking-related stimulus or scene (e.g. a close-
up of a cigarette) matched on age, sex, complexity and
ethnicity to another photograph containing no smoking-
related content. In the assessment version of the visual
probe task and pictorial Stroop task, 12 picture pairs will
be used (picture pairs 1–12). Similarly in the AR and PT
versions of the visual probe task, the 12 picture pairs
consist of 6 picture pairs featured in the assessment ver-
sion of the task (picture pairs 6–12) in addition to 6
new picture pairs (picture pairs 13–18). An extra 4 neu-
tral picture pairs will be used for practice trials before
each task.
Clinic Tasks
 Visual probe task
At the baseline session and again at 4 weeks
post-quit, 8 weeks, 3 months and 6 months, all
participants complete the assessment version of
the visual probe task. The assessment version,
which will be used to measure attentional bias,
comprises a total of 192 trials, presented in two
blocks. Each trial begins with a fixation cross
displayed in the centre of the computer screen
for 500 ms. A picture pair of smoking-related
and neutral pictures is then presented side-by-side on
the screen for 500 ms. After this picture pair
Table 1 Treatment and assessment schedule
Session Treatment Measures
Baseline (week −2) Withdrawal-oriented behavioural support • Baseline questionnaire [demographics, smoking history, Fagerstrom
Test for Nicotine Dependence (FTND)]
• Mood and Physical Symptoms Scale (MPSS)
• Exhaled carbon monoxide (CO)
• Attentional bias assessment (visual probe and Stroop tasks)
Pre-quit visit (week −1)
Randomisation week
1 week supply nicotine patches Withdrawal-oriented
behavioural support Intervention group receives
attentional retraining (AR). Control group receives
placebo training (PT)
• CO
• MPSS
• VAS measure of craving (pre & post cue exposure task)
Quit day (week 0) 1 week supply nicotine patches Withdrawal-oriented
behavioural support Intervention group receives AR
Control group receives PT
• CO
• MPSS
Post-quit visits
(weeks +1, +2, +3)
1 week supply nicotine patches Withdrawal-oriented
behavioural support Intervention group receives AR.
Control group receives PT
• CO
• MPSS
• Lapses recorded on electronic diary
Week +4 post-quit visit 4 week supply nicotine patches Withdrawal-oriented
behavioural support
• CO
• MPSS
• Attentional bias assessment (visual probe and Stroop tasks)
• VAS measure of craving (pre & post cue exposure task)
• Group allocation assessment
• Lapses recorded on electronic diary (up to +5 weeks) thereafter
reported in clinic CRF
Week +8 post-quit visit 4 week supply transdermal nicotine patches
(where eligible)
• CO
• MPSS
• Attentional bias assessment (visual probe and Stroop tasks)
• VAS measure of craving (pre & post cue exposure task)
• Lapses reported in clinic CRF
3 months post-quit visit • CO
• MPSS
• Attentional bias assessment
• (visual probe and Stroop tasks)
• VAS measure of craving (pre & post cue exposure task)
• Lapses reported in clinic CRF
6 months post-quit visit • CO
• MPSS
• Attentional bias assessment (visual probe and pictorial Stroop tasks)
• VAS measure of craving (pre & post cue exposure task)
• Lapses reported in clinic CRF
• Patient satisfaction questionnaire
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formerly occupied by one of the pictures. This probe
is either a circle or square. Participants are required to
discriminate the identity of the probe and respond
accordingly by pressing the up or down arrow keys
on the keyboard as quickly as possible. There is a
500 ms interval before the next trial. Presentation
of each picture-pair and probe location is
counterbalanced. In all trials, the visual probe
replaces the smoking-related and neutral pictures
with equal frequency. At the start of the task,
participants carry out 8 practice trials in which
neutral picture pairs are presented first, to allow
them to become familiar with the procedure.
Each block of trials is presented in a new random
order for each participant, using EPrime version 2
(Psychology Software Tools Inc., Pittsburgh PA).
The task takes approximately 16 minutes.
Attentional bias scores will be calculated fromreaction time (RT) data; an attentional bias towards
smoking cues is characterized by faster reaction
times towards smoking-related pictures than
neutral pictures.
 Pictorial Stroop task
All participants will carry out a pictorial Stroop task
as an additional measure of cognitive bias. The
pictorial Stroop task will be given after the visual
probe task at the baseline session and again at
4 weeks post-quit, 8 weeks, 3 months and 6 months.
The task comprises a total of 192 trials, presented in
four blocks of 48 trials, with each block consisting of
smoking-related pictures or neutral pictures only.
Each picture is presented centrally on a computer
screen with either an outline of a red, blue, yellow
or green border. Participants are required to indicate
the colour of the border, while ignoring the picture,
by pressing one of four corresponding labelled keys
on the keyboard, as quickly as possible. Participants
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presented first, to allow them to become familiar
with the procedure. A short break between blocks
will be permitted.
Each block of trials is presented in a new random
order for each participant, using EPrime version 2
(Psychology Software Tools Inc., Pittsburgh PA).
The task takes approximately 12 minutes to
complete. Stroop bias scores will be calculated from
RT data; selective processing of smoking cues is
characterized by slower reaction times towards
smoking-related pictures than neutral pictures.
 Cue exposure task
At 1 week prior to quit day, 4 weeks post-quit and
follow-up sessions at 8 weeks, 3 months and
6 months, participants in both groups will be given
a cue exposure procedure to measure cue-induced
craving immediately after completion of the visual
probe task and pictorial Stroop task. This is a
common procedure in cue-reactivity research
[49,50]. Showing a strong craving response to cue-
exposure has been shown to predict relapse risk
[51]. Prior to attending the session at week −1,
participants will be instructed to abstain from
smoking for at least 1 hour. We chose an abstinence
period of 1 hour to avoid floor effects in craving
ratings, commonly found immediately after
smoking [52].
In order to standardize the procedure, instructions
for the cue exposure task will be recorded on a
digital recorder and then played to participants in
the relevant clinic sessions. Before the instructions
are played, participants will provide a single rating of
their urge to smoke on the VAS. The therapist will
place a box that conceals a cigarette and a lighter in
front of the participant. The recording will then be
played, which instructs the participant to lift up the
box and handle the cigarette and lighter contained
within. The task lasts 3 minutes. Following the task,
participants will provide another rating of their urge
to smoke on the VAS.Control group
Participants allocated to the control group will carry out
5 weekly sessions of PT, starting 1 week prior to their
designated quit day. During each session, participants
perform 8 practice trials of neutral picture pairs followed
by 192 trials of PT, presented in a block of two. Between
each block, participants are permitted to have a short
break if required. The task takes approximately 16 minutes
to complete. On each PT trial, the visual probes always
replace smoking-related and neutral pictures with equal
frequency.Intervention group
Participants allocated to the AR group will carry out 5
weekly sessions of the modified visual probe task, AR,
starting 1 week prior to their designated quit day. Eight
practice trials of neutral picture pairs are presented prior
to the first block of AR trials. A total of 192 training tri-
als are presented in a block of two, where participants
have the opportunity to have a break in between. The
task takes approximately 16 minutes to complete.
The AR program differs from the PT program only
in the location of the visual probes. During each
training trial, visual probes always appear in the loca-
tion of the neutral pictures. Thus, participants always
have their attention directed away from smoking-related
pictures.
Stop smoking treatment
Systematic reviews have shown that some behavioural and
pharmacological interventions increase people’s chances
of successfully stopping smoking [53,54]. All participants
will therefore be given NRT and receive standard with-
drawal orientated behavioural support [38].
Participants in this trial will be offered 21 mg/24 hour
nicotine patches as the only choice of treatment. This
is because:
1) All participants will be regular smokers for whom
the 21 mg dose is deemed appropriate.
2) The study aims to examine the effects of AR on urge
to smoke. Short-acting NRT e.g. inhalator or gum
affect cue-induced urges to smoke and reduce their
intensity [55]. It would thus be difficult to assess
the effects of the AR if short-acting NRT is used.
Participants are also not permitted to use vareni-
cline for the same reason [56]. Investigators have
found that nicotine patches do not protect against
cued craving [57], therefore we consider that
patch-use is unlikely to mask the potential effects
of retraining.
3) The patch is the best tolerated form of NRT and has
the highest adherence [58,59].
Dose alteration procedure
Nicotine patches are well tolerated in the large majority
of regular smokers and so we expect that most people
will continue with the standard dose. However, there are
circumstances when the form or dose of the preparation
needs to be changed. This variation reflects pragmatic
behaviour in the NHS SSS and is expected to be equal in
both arms. We anticipate the following occurrences:
1) Minor skin irritation to the patch is one of the most
common problems with use. This is commonly
eased by swapping from one form of patch to
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If the skin reaction is worse, such as causing blisters
that cannot be remedied by emollients and
hydrocortisone cream, patch use will be stopped and
the participant will be swapped to an equivalent
dose of oral NRT.
2) Sleep disturbance or vivid dreaming is also one of
the most common problems with use of the nicotine
patch. This can usually be eased by removing the
nicotine patch an hour or so before bedtime and so
this will be advised. There is no good evidence that
16 hour patch use is less effective than 24 hour
patch use.
3) Possible symptoms that dose is too high are
uncommon problems, but possible. Nausea is the
earliest symptom of overdose, but it is also a
common symptom experienced by people often
enough. Nicotine has a short half life, meaning that
by about 10 hours after first applying a patch,
nicotine has reached a steady state. Therefore
nausea occurring for the first time days after starting
treatment is unlikely to be due to the patch. More
definite symptoms are as follows, muscular
twitching, dizziness, confusion, rapid pounding
heart, high blood pressure, vomiting, and weakness.
However, 21 mg/24 hour patch systems come as
14 mg/24 hours and 7 mg/24 hours, which can be
used in a step down system. If the therapist thinks
that an overdose is likely, the precaution will be to
step down the dose to the next step i.e. from 21 mg
to 14 mg, or from 14 mg to 7 mg.
Duration of treatment and instructions for use
Treatment with NRT will start either on the evening
prior to quit day or the morning of quit day, depending
on personal preference. Patches will be dispensed ac-
cordingly during the second visit, which is 1 week prior
to quit day. Instructions for patch use include changing
it every 24 hours, using a different area of skin for the
new patch. Participants will be advised to continue using
the patch for at least 8 weeks or stop if they abandon
their quit attempt before the 8 weeks. The therapist in
consultation with the patient may choose to step down
the patch as discussed above. Step down is not necessary
as there is no evidence to suggest that it enhances effi-
cacy, but it is commonly perceived as helpful by patients.
Step down towards the end of treatment will not be per-
mitted to commence until at least 4 weeks after quit
day. The therapist will be instructed not to suggest step-
ping down in people who have had recent lapses. Some
organisations we are working with do not allow treat-
ment for longer than 8 weeks, but, in those that do, the
therapist should consult the participant about longer
courses of treatment up to 12 weeks duration. Thisdecision will be at the discretion of the therapist in con-
sultation with the patient.
Behavioural support will start 2 weeks prior to quit day,
and last up to 4 weeks after quit day. This follows the typ-
ical 7-session withdrawal orientated therapy programme
offered in existing NHS SSS [38].
Reporting of adverse events
This is not a trial of an investigational medical product.
We are using a licensed medical product within the terms
of its license and in accord with clinical guidelines. We
therefore expect relatively few problems and so there
are no special reporting requirements. The therapist
leading the sessions will manage problems within his/
her own competence. Clinical advice will be sought from
the trial doctor. Between them, the therapist and trial doc-
tor will decide how to manage unexpected problems
and whether to report a suspected unexpected serious
adverse reaction (SUSAR) to the Medicines and Health
Care Regulatory Authority using the yellow card system
(this is a standard system for reporting unusual reac-
tions to medication).
However, for the purposes of the trial, we will record
clinically significant adverse events that lead to a change
in medication management or is considered to be sig-
nificant otherwise. This will allow us to track changes in
medication instruction, such as swapping to 16 hour use
or dose alterations. The CRF will be used to record the
date, the nature of the adverse event/symptoms, and the
action taken.
Primary trial outcomes
 Measure of attentional bias during assessment
trials of the visual probe task, as measured by the
difference in median reaction time (ms) taken to
respond to probes replacing smoking-related
stimuli versus probes replacing neutral stimuli.
This will be assessed at 4 weeks post-quit in
abstinent and non-abstinent smokers across both
trial arms, following recommendations of
Shiffman et al. [60].
 Strength of weekly urge to smoke on the MPSS,
measured up to 4 weeks post-quit in abstinent and
non-abstinent smokers across both trial arms.
Secondary trial outcomes
 Strength of weekly withdrawal symptoms on the
MPSS, measured up to 4 weeks post-quit in
abstinent and non-abstinent smokers across both
trial arms.
 Prolonged abstinence measured and biochemically
validated at 4 weeks post-quit and each follow-up
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Russell standard includes a 2 week grace period
from quit day, followed by smoking no more than
5 cigarettes and verification by means of exhaled
CO, with a cut-off point of <10 ppm.
 Time to first lapse, with a lapse episode defined here
as any smoking, even a puff [39].
Other trial outcomes
 Feasibility of running the ARTS trial within NHS
SSS assessed on the basis of:
- Rates of response to patient invitation letters;
- Rates of recruitment at telephone screening;
- Rates of attendance at clinic visits;
- Rates of drop out prior to and after
randomisation.
 User acceptability as measured by ratings of
perceived usefulness on a patient satisfaction
questionnaire.
 Change in cue-induced cravings measured on the
VAS prior to and at the end of the cue-exposure
task at 4 weeks, 8 weeks, 3 months and 6 months
post-quit day in abstinent and non-abstinent
smokers across both trial arms.
 Measure of cognitive processing bias on the pictorial
Stroop task, to assess generalisation of AR effects at
4 weeks post-quit in abstinent and non-abstinent
smokers across both trial arms. Stroop bias will be
measured by the difference in median reaction time
taken to respond to colour-naming of smoking-related
stimuli versus colour-naming of neutral stimuli.
 Measure of attentional bias towards novel untrained
stimuli on the visual probe task at 4 weeks post-quit
in abstinent and non-abstinent smokers across both
trial arms.
 Measure of attentional bias on the visual probe
task and pictorial Stroop task at 8 weeks,
3 months and 6 months to assess long term
effects of AR.
 Strength of urge to smoke and withdrawal
symptoms on the MPSS, measured up to 8 weeks,
3 months and 6 months to assess long term effects
of AR.
Power calculation
The sample size is based on the following. In these cal-
culations, we assume that only quitters will continue to
attend clinic and that the measures will be analysed pri-
marily in abstinent smokers, as is standard practice with
withdrawal phenomena [60].
We assume conservatively that the effect of 5 ses-
sions of AR will be no greater than the effect of a sin-
gle session. From the findings of the Attwood et al.study [26], to detect a mean reduction of 26 ms (SD =
43 ms) with 80% power and a type 1 error rate of 5%, 42
participants in each group will be required. We revised
this calculation to adjust for baseline attentional bias
scores. In our pilot study of AR, we found an estimated
correlation coefficient of −0.13 between baseline and post-
training measurements. Thus, to detect a reduction of
26 ms with the same standard deviation, power and type
1 error stated above, 42 participants are still required in
each group. We expect that at least 50% of participants
will reach the Russell standard abstinence criteria at
4 weeks, as the NHS services achieve greater than this,
providing about 50 abstinent participants in each arm,
sufficient to test this hypothesis.
The trial is an exploratory study but is powered to
detect differences in urge to smoke. One study on
smokers quitting on pharmacotherapy found that the
mean change in urge strength between quit day and
week 1 was about 0.5 points measured with the MPSS
and had a standard deviation of 1.2 [61]. Another study
reported that glucose reduced urge strength by 1.0
points, although this was immediately after dosing [62].
In both of these studies, MPSS urge strength was scored
0–5 [42]. We assume that if AR can reduce urge strength
by 0.6 points, then 62 participants in each group will be
needed to detect this with 80% power and a type 1 error
rate of 5%. From the earlier study [61] we used an esti-
mated correlation coefficient of 0.41 between quit day
and post-training urge strength to adjust this power cal-
culation. This means that to detect a 0.6 point reduction
in urge strength (SD = 1.2) with 80% power and a type 1
error rate of 5%, 53 participants would be required in
each group. In the first 4 weeks, when withdrawal is at
its height, this implies that about 200 smokers will be
needed, assuming that 60% will achieve abstinence in
the first 4 weeks.
The trial is not large enough to detect the effects
of AR on prolonged abstinence as several hundred
participants would be needed. With a sample size of
200 smokers, if AR increased abstinence rates by 30%
(RR = 1.3), we have approximately 57% power to detect
a difference in the proportion abstinent, using a two-
sided test with a type 1 error rate of 5% and assuming
an abstinence rate of 50% in the control group.
Loss to follow-up
Participants who fail to attend clinic and do not respond
to our telephone calls will be classed as smokers for the
analysis of smoking abstinence, as is standard [39]. We
expect to make contact with more than 90% of people at
6 month follow-up, based on experiences of a recent
trial [61]. We anticipate that the effects of AR on atten-
tional bias and withdrawal phenomena will be analysed
primarily in abstinent smokers, as recommended by
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clinic appointments by failed quitters is not considered a
threat on the integrity of the trial. We therefore do not
require those participants who failed to maintain abstin-
ence and abandoned their quit to continue to attend
clinics except for reasons detailed below.
This study could give valuable information on what
happens to attentional bias over time, how it is affected
by training, how it is affected by resuming smoking, and
whether the training effect is contingent on continued
abstinence. Accordingly, we will ask all participants re-
gardless of smoking status to attend the follow-up visits.
Adequate compensation should increase the likelihood
of attendance.
Analysis
 Primary analyses
Attentional bias scores on the visual probe task will
be calculated by subtracting median RTs to probes
that replace smoking-related pictures from median
RTs to probes that replace neutral pictures, with
positive scores indicating a bias towards smoking
cues and negative scores indicating a bias towards
neutral cues. Median RTs will be used because distri-
butions of mean RTs are often reported as skewed
[33,63]; therefore we do not need to set parameters
for outlying RTs. Bias scores, as measured at 4 weeks
post-quit, will be used to examine AR effects on
attentional bias firstly by trial arm and secondly by
abstinence status using ANCOVA. An alpha level of
0.05 will be used. These analyses will be performed
using PASW Statistics 18 (SPSS, Inc., 2009, Chicago,
IL, USA).
To investigate AR effects on weekly urge to smoke,
data will be analysed using a mixed effects
regression model with an autoregressive variance-
covariance structure, to allow for variations in
craving between participants. This will enable all
weekly time points to be included and modelled
simultaneously. An autoregressive modelling
structure takes into consideration that repeated
craving measurements taken closer together in time
on the same participant are likely to be more highly
correlated than measurements that are taken further
apart in time [64]. This modelling technique will be
used for MPSS composite scores for urge to smoke
(MPSS-C). Regression coefficients, p-values and 95%
confidence intervals (CI) will be derived from the
models. These analyses will be undertaken using
Stata 12.0 (StataCorp, 2011, College Station, TX:
StataCorp LP).
Intention-to-treat analyses will be performed to
account for people who drop out of treatment. Secondary analyses
Effects of AR on withdrawal will be examined using
the same technique stated for urge to smoke
analyses, in a mixed effects regression model of
composite scores for withdrawal symptoms (MPSS-M).
We will control for baseline MPSS-M scores, as is
standard for the MPSS [42].
To determine the proportion of people achieving
abstinence by trial arm, risk ratios (RRs) will be
calculated with corresponding 95% CIs. Those
reported as lost-to-follow up will be counted as non-
abstinent, as is standard in the reporting of smoking
cessation trials [39,65].
Proportional hazards modelling will be used to
analyse the median time to lapse by trial arm;
hazard ratios (HRs) will be reported with
corresponding 95% CIs. These analyses will be
performed using Stata 12.0 (StataCorp, 2011,
College Station, TX: StataCorp LP).
 Additional analyses
We will adjust analyses of attentional bias scores,
MPSS-C scores and MPSS-M scores for potential
moderators of attentional bias, urge to smoke and
withdrawal symptoms. These will include age,
gender and FTND across all analyses. Pre-quit urge
to smoke will also be examined in the model of
attentional bias scores and pre-quit attentional bias
in the models of MPSS-C and MPSS-M.
To investigate longer-term retraining effects, we will
analyse 8 week, 3 month and 6 month post-quit data
for attentional bias scores using ANCOVA and
mixed-effects regression models for MPSS-C scores
and MPSS-M scores, as stated previously.
To examine AR effects on cue-induced craving, VAS
scores will be analysed in the same way as MPSS-C
and MPSS-M scores, in mixed-effects regression
models. Visual analogue scale scores will be
calculated from measurements taken from a
0–100 mm scale before and after the cue exposure
task, which are administered 1 week before quit day
and again at 4 weeks, 8 weeks and 3 months
post-quit. The difference between pre and post
measurements will be calculated and the change in
cue-induced craving over time will be reported.
Generalisation of AR to other cognitive bias
measures will be assessed using RT scores from the
pictorial Stroop task. Stroop bias scores will be
calculated by subtracting median RTs to probes that
replace neutral pictures from median RTs to probes
that replace smoking-related pictures. Slower RTs
towards smoking-related pictures indicate a bias
towards smoking cues. Again, parameters for outlying
RTs do not need to be defined as median rather than
mean RTs will be used. Bias scores, as measured at
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on Stroop bias firstly by trial arm and secondly by
abstinence status using ANCOVA.
Similarly, we will assess whether AR generalises to
untrained novel stimuli that only appear in the
assessment versions of the visual probe task and not
during training sessions. Attentional bias scores for
the trained and untrained stimuli will therefore be
analysed separately using ANCOVAs.
Responses to the patient satisfaction questionnaire
and identification of group allocation will be
compared across trial arms as percentages.Ethics and research governance
The trial will be conducted in compliance with the prin-
ciples of the Declaration of Helsinki (1996), the ICH-
GCP, the EU Clinical Trials Directive and all applicable
regulatory requirements. The study protocol and other
documentation were approved by the National Research
Ethics Committee (10/H1206/34) and local NHS Research
& Development offices. Subsequent protocol amendments
will be submitted to the Research Ethics Committee for
approval, and the other bodies where necessary. We will
provide the Research Ethics Committee with annual pro-
gress reports, in addition to a final study report.
Discussion
This is the first trial to assess the potential clinical trans-
lation of AR procedures in smokers attempting to quit
using NHS SSS. Multiple sessions of AR might increase
treatment efficacy on top of standard treatment, as dem-
onstrated in a recent trial of alcohol-dependent patients
[33]. If effective, not only could AR be used in stop
smoking clinics, it could also be offered as a web-based
intervention on NHS stop smoking websites as another
potentially low-cost alternative.
Several procedures are in place to minimise potential
sources of bias. To minimise the risk of selection bias,
we are using a simple random sequence for assigning
participants to groups. To minimise performance bias,
we are blinding all therapists and participants to group
allocation, though there is a risk of participants becom-
ing aware of which group they have been assigned to
while carrying out the task itself. At follow up, we will
assess participants’ knowledge of which intervention
they believe to have received.
While this trial offers the ability to examine AR as a
therapeutic tool, data on attentional bias and its relation to
urges to smoke, cue-induced cravings and resumption of
smoking will enhance our understanding of relapse and
possible preventative strategies. Knowing how urges to
smoke strike, their antecedents and smoker’s responses
to these are a key part of designing future intervention
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